2019
Safely and Effectively Evaluating Computed Tomography–detected Lung Lesions. Much Work to Be Done
Burks AC, Gould MK, Silvestri G, Yarmus LB, Sears CR, Arenberg DA, Gonzalez AV, Slatore CG, Tanner NT, Vachani A, Nana-Sinkam P, Fuster MM, Wahidi MM, Tanoue LT, Rivera MP. Safely and Effectively Evaluating Computed Tomography–detected Lung Lesions. Much Work to Be Done. Annals Of The American Thoracic Society 2019, 16: 1360-1362. PMID: 31437410, DOI: 10.1513/annalsats.201905-389ps.Peer-Reviewed Original Research
2018
Improved discrimination between benign and malignant LDCT screening-detected lung nodules with dynamic over static 18F-FDG PET as a function of injected dose
Ye Q, Wu J, Lu Y, Naganawa M, Gallezot JD, Ma T, Liu Y, Tanoue L, Detterbeck F, Blasberg J, Chen MK, Casey M, Carson RE, Liu C. Improved discrimination between benign and malignant LDCT screening-detected lung nodules with dynamic over static 18F-FDG PET as a function of injected dose. Physics In Medicine And Biology 2018, 63: 175015. PMID: 30095083, PMCID: PMC6158045, DOI: 10.1088/1361-6560/aad97f.Peer-Reviewed Original ResearchConceptsPopulation-based input functionStandardized uptake valueImage-derived input functionLung nodulesClinical trialsTime-activity curvesLow-dose computed tomography (LDCT) screeningLung cancer mortality ratesIndeterminate lung nodulesComputed Tomography ScreeningF-FDG PETCancer mortality ratesStatic PET acquisitionVirtual clinical trialsScan durationTomography screeningFDG injectionPET scansMortality rateUptake valueAccurate diagnosisMalignant lung nodulesROC analysisPatient dataMalignant nodules
2015
Lung Cancer Screening
Tanoue LT, Tanner NT, Gould MK, Silvestri GA. Lung Cancer Screening. American Journal Of Respiratory And Critical Care Medicine 2015, 191: 19-33. PMID: 25369325, DOI: 10.1164/rccm.201410-1777ci.Peer-Reviewed Original ResearchConceptsLow-dose computed tomographyLung cancerUnited States Preventive Services Task ForcePack-year smoking historyNational Lung Screening TrialLung cancer screeningUnnecessary invasive testingFalse-positive findingsAspects of screeningLDCT screeningSmoking historyCancer screeningMortality burdenInvasive testingHigh riskScreening TrialComputed tomographyRisk of harmAge 55Positive findingsCancerEffective screeningPossible harmScreeningTask Force
2006
Evaluation and definitive management of medically inoperable early stage non-small-cell lung cancer. Part 2: newer treatment modalities.
Decker RH, Tanoue LT, Colasanto JM, Detterbeck FC, Wilson LD. Evaluation and definitive management of medically inoperable early stage non-small-cell lung cancer. Part 2: newer treatment modalities. Oncology 2006, 20: 899-905; discussion 905-8, 913. PMID: 16922260.Peer-Reviewed Original ResearchConceptsCell lung cancerLung cancerPoor baseline pulmonary functionCurative treatment alternativeInoperable early stageSingle-modality radiotherapyComorbid medical illnessesBaseline pulmonary functionBetter overall survivalMinority of patientsRadiotherapy dose escalationDefinitive treatment optionEarly-stage patientsOverall survival dataNew treatment modalitiesMediastinal nodalAdvanced diseaseCurative resectionDistant failureOverall survivalPulmonary functionDose escalationDefinitive managementMedical illnessCancer mortality